Christopher J. Nardo
First SEC filing: Aug. 12, 2021 · Latest: Aug. 12, 2021
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | DRMA | A | 18,000 | · | · | 18,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Jan. 13, 2025 | DRMA | A | 20,000 | · | · | 20,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Jan. 4, 2024 | DRMA | A | 50,000 | · | · | 50,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Jan. 3, 2023 | DRMA | A | 100,000 | · | · | 100,000 Direct | · | Acquired | (price as of 2026-10-05) |
| July 1, 2022 | DRMA | A | 30,000 | · | · | 30,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Jan. 3, 2022 | DRMA | A | 30,000 | · | · | 30,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Aug. 17, 2021 | DRMA | C | 50,000 | · | · | 0 Indirect | -100.00% | Disposed | (price as of 2026-10-05) |
| Aug. 17, 2021 | DRMA | C | 2,439 | · | · | 2,439 Indirect | · | Acquired | (price as of 2026-10-05) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | DRMA | Stock Option (right to buy) | Common Stock | $2.18 | Jan. 1, 2036 | 18,000 | Acquired |
| Jan. 13, 2025 | DRMA | Stock Option (right to buy) | Common Stock | $1.38 | Jan. 12, 2035 | 20,000 | Acquired |
| Jan. 4, 2024 | DRMA | Stock Option (right to buy | Common Stock | $0.61 | Jan. 3, 2034 | 50,000 | Acquired |
| Jan. 3, 2023 | DRMA | Stock Option (right to buy) | Common Stock | $0.31 | Jan. 2, 2033 | 100,000 | Acquired |
| July 1, 2022 | DRMA | Stock Option (right to buy) | Common Stock | $0.51 | June 30, 2032 | 30,000 | Acquired |
| Jan. 3, 2022 | DRMA | Stock Option (right to buy) | Common Stock | $1.88 | Jan. 2, 2032 | 30,000 | Acquired |
| Aug. 17, 2021 | DRMA | Series 1 Preferred Stock | Common Stock | · | · | 50,000 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 8 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Aug. 12, 2021 | DRMA | Common Stock | 25,121 | Direct |
| Aug. 12, 2021 | DRMA | Stock Option (Right to Buy) | · | Direct |
| Aug. 12, 2021 | DRMA | Stock Option (Right to Buy) | · | Direct |
| Aug. 12, 2021 | DRMA | Stock Option (Right to Buy) | · | Direct |
| Aug. 12, 2021 | DRMA | Stock Option (Right to Buy) | · | Direct |
| Aug. 12, 2021 | DRMA | Stock Option (Right to Buy) | · | Direct |
| Aug. 12, 2021 | DRMA | Stock Option (Right to Buy) | · | Direct |
| Aug. 12, 2021 | DRMA | Series 1 Preferred Stock | · | Indirect |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $336,000 | $107,520 | · | $26,450 | · | · | · | $469,970 |
| 2022 | $297,917 | $32,000 | · | $63,390 | · | · | · | $393,307 |
| 2021 | $270,000 | $86,400 | · | $322,504 | · | · | · | $678,904 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.